Followers | 839 |
Posts | 120698 |
Boards Moderated | 13 |
Alias Born | 09/05/2002 |
Thursday, September 12, 2024 12:25:36 PM
https://finance.yahoo.com/news/moderna-r-d-day-highlights-100000130.html
Annual R&D expenses, expected to be $4.7B in 2024, will be reduced to $3.6-3.8B by 2027. Cumulatively, R&D expenses during the 2025-2028 period will be reduced by 20%. Such a cutback is apparently too little and too slow to placate investors.
Perhaps more important, MRNA now says it expects to reach break-even cash flow in 2028—two years later then the previous guidance.
Moreover, MRNA issued 2025 revenue guidance of $2.5-3.5B, which is down from the (previously reduced) 2024 guidance of $3.0-3.5B (#msg-174849487).
Please see #msg-175048423 for related info.
“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”
Recent MRNA News
- Carisma Unveils Promising Pre-Clinical Data on Anti-GPC3 In Vivo CAR-M Therapy for Hepatocellular Carcinoma • PR Newswire (US) • 11/08/2024 12:30:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/07/2024 09:03:09 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/07/2024 11:33:51 AM
- U.S. Futures Rise as Investors Await Fed Rate Decision; Oil Prices Drop • IH Market News • 11/07/2024 11:19:35 AM
- Trump Media Shares Surge 32% Pre-Market; Tesla Jumps 13%; Coinbase Rises with BTC All-Time High • IH Market News • 11/06/2024 11:09:49 AM
- Carisma Therapeutics to Present New Data on Anti-GPC3 In Vivo CAR-M Therapy for Hepatocellular Carcinoma at SITC 2024 • PR Newswire (US) • 11/05/2024 02:05:00 PM
- Merck and Moderna Initiate Phase 3 Trial Evaluating Adjuvant V940 (mRNA-4157) in Combination with KEYTRUDA® (pembrolizumab) After Neoadjuvant KEYTRUDA and Chemotherapy in Patients With Certain Types of Non-Small Cell Lung Cancer (NSCLC) • Business Wire • 10/28/2024 10:45:00 AM
- Flagship Pioneering Announces Appointment of Junaid Bajwa as Senior Partner, Head of United Kingdom, and Science Partner for Pioneering Intelligence • PR Newswire (US) • 10/23/2024 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 10/08/2024 08:19:25 PM
- Shareholders of Moderna, Inc. Should Contact The Gross Law Firm Before October 8, 2024 to Discuss Your Rights - MRNA • PR Newswire (US) • 10/07/2024 09:45:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 10/04/2024 12:52:56 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 10/04/2024 12:49:56 PM
- Invaio Sciences Appoints André Andonian as Chairman of the Board of Directors • PR Newswire (US) • 10/03/2024 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/02/2024 11:03:59 AM
- The Gross Law Firm Notifies Moderna, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline • PR Newswire (US) • 09/30/2024 09:45:00 AM
- Shareholders that lost money on Moderna, Inc.(MRNA) Urged to Join Class Action - Contact The Gross Law Firm to Learn More • PR Newswire (US) • 09/26/2024 09:45:00 AM
- Moderna, Inc. Sued for Securities Law Violations - Contact The Gross Law Firm Before October 8, 2024 to Discuss Your Rights - MRNA • PR Newswire (US) • 09/23/2024 09:45:00 AM
- The Gross Law Firm Reminds Moderna, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of October 8, 2024 - MRNA • PR Newswire (US) • 09/19/2024 09:45:00 AM
- The Gross Law Firm Notifies Moderna, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline • PR Newswire (US) • 09/16/2024 09:45:00 AM
- OpenAI Unveils Strawberry AI Model Series; Boeing Stock Falls 4% Amid Strike; HR Surges 20% on Growth Forecast • IH Market News • 09/13/2024 10:12:55 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/12/2024 10:03:14 AM
- Moderna, Inc. Sued for Securities Law Violations - Investors Should Contact The Gross Law Firm for More Information - MRNA • PR Newswire (US) • 09/12/2024 09:45:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/10/2024 08:15:27 PM
- Carisma and Moderna Expand Collaboration to Develop Two In Vivo CAR-M Therapies for Autoimmune Diseases • PR Newswire (US) • 09/10/2024 11:30:00 AM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 09/09/2024 07:29:35 PM
SANUWAVE Announces Record Quarterly Revenues: Q3 FY2024 Financial Results • SNWV • Nov 8, 2024 7:07 AM
DBG Pays Off $1.3 Million in Convertible Notes, which Retires All of the Company's Convertible Notes • DBGI • Nov 7, 2024 2:16 PM
SMX and FinGo Enter Into Collaboration Mandate to Develop a Joint 'Physical to Digital' Platform Service • SMX • Nov 7, 2024 8:48 AM
Rainmaker Worldwide Inc. (OTC: RAKR) Announces Successful Implementation of 1.6 Million Liter Per Day Wastewater Treatment Project in Iraq • RAKR • Nov 7, 2024 8:30 AM
SBC Medical Group Holdings and MEDIROM Healthcare Technologies Announce Business Alliance • SBC • Nov 7, 2024 7:00 AM
VAYK Confirms Insider Buying at Open Market • VAYK • Nov 5, 2024 10:40 AM